Exhibitor Product Theaters


In-Person Exhibitor Product Theater

Open to all in-person ACG 2021 attendees. These presentations provide additional educational opportunities for attendees. No CME is provided for Theater presentations. The Exhibitor Product Theater is located in booth 1413 in the Shoreline Exhibit Hall.

Sunday, October 24

Knowledge Is Power

Miguel D. Regueiro, MD, FACG
5:15 pm – 6:00 pm
An interactive discussion of Crohn's disease data led by IBD expert Miguel Regueiro.
This program is sponsored by AbbVie.

* A New Once-Daily Oral Treatment Option for Your Adult Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Stephen B. Hanauer, MD, MACG
6:15 pm – 7:00 pm
Please join us for a presentation on the first and only sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of moderately to severely active UC in adults. In this program, Dr. Hanauer will provide an overview of the role of S1P signaling in UC, as well as the efficacy and safety data for ozanimod.
This program is sponsored by Bristol Myers Squibb.

Monday, October 25

Treatment Considerations for the Active Management of IBS

Philip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG
10:30 am – 11:30 am
Please join us for a LIVE product theater with Dr. Philip Schoenfeld to review clinical data on treatment options that may help your adult patients with IBS-C, CIC and IBS-D.
This program is sponsored by AbbVie & Ironwood Pharmaceuticals.

Rethinking First-line Treatment of Helicobacter pylori

Neil H. Stollman, MD, FACG
12:45 pm – 1:20 pm
It is a promotional program sponsored by RedHill that is designed to educate and inform HCPs and/or Patients about the benefits, risks, and appropriate uses of Talicia, as well as topics that support the day-to-day care of Patients. It will provide information on Talicia, H. pylori for which the product is indicated.
This program is sponsored by RedHill Biopharma.

Discuss the diagnosis of Exocrine Pancreatic Insufficiency (EPI) and the treatment with CREON.

Nathaniel Ranney, MD
1:40 pm – 2:15 pm
Discuss the diagnosis of Exocrine Pancreatic Insufficiency (EPI) and the treatment with CREON.
This program is sponsored by AbbVie.

* The Power of the Microbiome – Can it be unlocked to break the cycle of recurrent Clostridioides difficile infection?

Carl Crawford, MD
3:45 pm – 4:45 pm
• Understand the role of the microbiome in overall health
• Explore the relationship between the gut microbiome and Clostridioides difficile infection (CDI)
• Review the risk factors and pathobiology of CDI
• Assess the current burden of CDI and recurrent infection
• Evaluate the current management of CDI and the potential of microbiome-based therapeutics
This program is sponsored by Ferring Pharmaceuticals, Inc.

Tuesday, October 26

Unmet Needs and The Role of Acid Suppression in the Treatment of H. pylori Infection

Linda Anh B. Nguyen, MD
10:35 am – 11:30 am
Join us for an engaging session on the unmet needs in the treatment of H. pylori infection, focusing on clinical presentation and patients who may be at higher risk, current treatment guidelines and challenges, as well as the role of acid suppression in antibiotic efficacy.
This disease state education is sponsored by Phathom Pharmaceuticals and is not a continuing medical education program.

STELARA® (ustekinumab): A FIRST-LINE BIOLOGIC OPTION
A Patient Journey and Treatment Considerations for Biologic-naïve Adult Patients with Moderately to Severely Active Ulcerative Colitis (UC)

Anita Afzali, MD, MPH, FACG
12:45 pm – 1:20 pm
Despite advances in UC management, knowledge gaps remain associated with first line biologic choice and the evolving treatment considerations throughout a patient’s journey. This program will examine treatment considerations through a patient case in UC and review the clinical efficacy and safety data for STELARA®, including the 3-year long-term extension data in UC.
This program is developed and sponsored by Janssen Biotech, Inc.

Understanding Acute Hepatic Porphyria (AHP): Unexplained, recurrent abdominal pain

Gregory S. Sayuk, MD, MPH
1:40 pm – 2:15 pm
Please join Dr. Greg Sayuk as he utilizes a case-based approach to provide an overview of acute hepatic porphyria (AHP), explore the long, often unpredictable patient journey with AHP, and highlight the importance of the gastroenterologist’s role in recognizing and testing for AHP. AHP is characterized by debilitating, potentially life-threatening attacks, of which the cardinal symptom is severe, diffuse abdominal pain, along with one or more other unexplained symptoms, which may include nausea or vomiting, psychological symptoms (anxiety or confusion), tachycardia, hypertension, and limb weakness or pain.
This program is sponsored by Alnylam Pharmaceuticals

* A recording of this presentation will be available to all ACG 2021 attendees on the official ACG Conference Platform after the live session through March 31, 2022.


Virtual Exhibitor Product Theater

Available to all ACG 2021 attendees on the ACG Conference Platform. These presentations provide additional educational opportunities for attendees. No CME is provided for Theater presentations.

Sunday, October 24

Perspectives on the Pathogenesis of Recurrent Clostridioides difficile Infection: Insights into Microbiome Science

Paul Feuerstadt, MD, FACG
5:15 pm – 6:00 pm
Discussion on the diagnosis, management, and treatment of recurrent C. difficile infection (rCDI) with particular emphasis on the role of the microbiome in recovery from rCDI.
This program is sponsored by Seres Therapeutics, Inc.

Monday, October 25

An Expert Panel Discussion on Updates in Eosinophilic Esophagitis (EOE) Management

Neil H. Stollman, MD, FACG; Jonathan L. Bayuk, DO
10:30 am – 11:30 am
Join us for an engaging, expert-led discussion on updates in the management of eosinophilic esophagitis (EoE). Leaders in Gastroenterology and Allergy/Immunology will discuss updates in the management of EoE. An opportunity for interactive Q&A with the expert panel will follow the presentation.
This program is sponsored by Takeda Pharmaceuticals U.S.A, Inc.

* Eosinophilic Esophagitis: A Clinical Perspective of Type 2 Inflammation

Kathryn A. Peterson, MD
12:45 pm – 1:20 pm
EoE is a progressive, local manifestation of underlying systemic Type 2 Inflammation, resulting in substantial QoL impairment. In this virtual event, an expert will discuss the effects of localized Type 2 inflammation on the esophagus and explain the coexisting nature of Type 2 diseases in patients with EoE.
This program is sponsored by Sanofi Genzyme and Regeneron.

Clinician Perspectives on Managing Patients With Short Bowel Syndrome (SBS): An Interactive Discussion

Syed-Mohammed Jafri, MD; Sukanya Subramanian, MD
3:45 pm – 4:45 pm
In this program, Drs. Syed-Mohammed Jafri and Sukanya Subramanian will review a treatment option for patients with short bowel syndrome (SBS) who are dependent on parenteral support (PS) and discuss their perspectives on SBS management during a Q&A session.
This program is sponsored by Takeda Pharmaceuticals U.S.A., Inc.
https://us02web.zoom.us/webinar/register/WN_gYJ19qRpTOGPXPxncYmnYg

Tuesday, October 26

A Clinical Overview of a Prescription Treatment for Patients With Moderately to Severely Active Ulcerative Colitis

Asher Kornbluth, MD
10:35 am – 11:30 am
Dr. Asher Kornbluth will discuss the clinical data and safety profile of a prescription treatment for adult patients with moderately to severely active ulcerative colitis.
This program is sponsored by Pfizer

*A recording of this presentation will be available to all ACG 2021 attendees on the official ACG Conference Platform after the live session through March 31, 2022.